Exhibit 10.2
                                                                  EXECUTION COPY


                          REGISTRATION RIGHTS AGREEMENT

         THIS REGISTRATION RIGHTS AGREEMENT is made and entered into as of
October 21, 2004 by and among Q-Med, Inc., a Delaware corporation ("Company");
and Quest Diagnostics Ventures LLC, a Delaware corporation ("Quest Diagnostics
").

                                    RECITALS:

         WHEREAS, the Company has issued to Quest Diagnostics 298,507 shares
(the "Shares"), pursuant to the terms of a Stock Purchase Agreement dated as of
the date hereof.

         NOW, THEREFORE, in consideration of the mutual promises contained
herein and other good and sufficient consideration, the receipt and adequacy of
which is hereby acknowledged, the parties hereto agree as follows:

1. Definitions

         The following terms, when used in this Agreement, will, unless
otherwise expressly provided, have the following meanings:

"Beneficial Owner" means a person who, directly or indirectly, through any
contract, arrangement, understanding, relationship or otherwise has or shares:

         (a) Voting power which includes the power to vote, or to direct the
         voting of, such security; and/or

         (b) Investment power which includes the power to dispose, or direct the
         disposition of, such security;

or who would otherwise be deemed to be the beneficial owner of any security
under Rule 13d-3 issued under the Exchange Act, as such Rule is amended from
time to time. A person that is the "Beneficial Owner" of any Warrants will be
deemed to be the Beneficial Owner of the Stock issuable pursuant to the
Warrants, whether or not the Warrants are then exercisable.

"Beneficially Owns" has a correlative meaning to "Beneficial Owner."

"Exchange Act" means the Securities Exchange Act of 1934, as it is or may be
amended.

"Fair Market Value" of a share of Common Stock as of any date means the closing
sales price of a share of Common Stock reported in The Wall Street Journal with
respect to trading on such date (or if no sale took place on such date, the
closing sales price reported on the most recent preceding date on which a sale
took place). If the Common Stock is no longer traded on the NASDAQ National

<PAGE>

Market, Small Cap Market or on any national securities exchange whose trading is
reported in The Wall Street Journal, the Fair Market Value of Common Stock shall
be determined by the a member firm of the New York Stock Exchange selected by
the Corporation and approved by the Holder. If the Corporation and Quest
Diagnostics are unable to agree on the selection of a member firm, then the
issue of selection of a member firm shall be submitted to the American
Arbitration Association.

"Holder" has the meaning set forth in Section 2.2.

"Person" means any individual, partnership, corporation, trust or unincorporated
organization, or a government or agency or political subdivision thereof.

"Proposed Registration" has the meaning set forth in Section 3. 1.

"Prospectus" means the prospectus included in any Registration Statement, as
amended or supplemented by any prospectus supplement with respect to the terms
of the offering of any portion of the Registrable Securities covered by such
Registration Statement and by all other amendments and supplements to the
prospectus, including post-effective amendments and all material incorporated by
reference in such prospectus.

"Registrable Securities" has the meaning set forth in Section2. 1.

"Registration Statement" means any registration statement of Company which
covers any of the Registrable Securities pursuant to the provisions of this
Agreement, including the Prospectus, amendments and supplements to such
Registration Statement, including post-effective amendments, all exhibits and
all material incorporated by reference in such Registration Statement.

"SEC" means the Securities and Exchange Commission.

"Share" means a share of Stock.

"Stock" means Company's common stock, par value $.001 per share.

"Trading Day" means any day that the NASDAQ is open for trading.

"Underwritten Registration" or "Underwritten Offering" means a Registration in
which securities of Company are sold to an underwriter for reoffering on a firm
underwriting basis to the public.

"Voting Securities" mean shares of Stock and any other securities that are
entitled to vote together as a single class with the Stock on all matters
submitted for the approval of the stockholders of Company.

2. Securities Subject to this Agreement

         2.1 Registrable Securities. The securities entitled to the benefit of
this Agreement (the "Registrable Securities") are (a) all Shares issued on the

                                       2
<PAGE>

date of this Agreement, and (b) all Shares received as share dividends or Shares
issued on stock splits, mergers, consolidations or other reorganizations with
respect to the Shares referred to in the preceding clause.

         2.2 Holders of Registrable Securities. No person will be considered a
Holder other than Quest Diagnostics or a direct or indirect wholly owned
subsidiary of Quest Diagnostics Incorporated or its successor.

3. Piggyback Registration

         3.1 Notice of Proposed Registration. Each time that Company proposes
for any reason to register any of its Shares under the Securities Act (a
"Proposed Registration"), on Form S-1, S-2 or S-3 or any similar or successor
forms, Company will promptly give written notice of such Proposed Registration
to Quest Diagnostics and will offer the Holders the right to request inclusion
of all or a portion of such Holder's Registrable Securities in the Proposed
Registration. Each Holder will have ten (10) Trading Days from the receipt of
such notice by Quest Diagnostics to deliver a written request specifying the
number of such Registrable Securities that such Holder intends to sell and such
Holder's intended method of disposition. In the event that the Proposed
Registration by Company is, in whole or in part, an Underwritten Offering, any
request under Section 3.2 must specify that the Registrable Securities be
included in the underwriting on the same terms and conditions as the Shares, if
any, otherwise being sold through underwriters under such Proposed Registration.

         3.2 Allocation. Upon receipt of a written request pursuant to Section
3.1 hereof, Company will promptly use its best efforts to cause all such
Registrable Securities to be included in the Proposed Registration, to the
extent required to permit sale or disposition as set forth in the written
request. Notwithstanding the foregoing, if the managing underwriter(s) of any
Proposed Registration determines and advises in writing that the inclusion of
all Registrable Securities proposed to be included in the Underwritten Offering
together with any other issued and outstanding Shares proposed to be included
therein by other stockholders would interfere with the successful marketing of
Company's Shares (or any Shares being sold by any other stockholder with demand
registration rights), then Company will not be required to register any
Registrable Securities in excess of the amount, if any, of Registrable
Securities which the managing underwriter(s) of such Underwritten Offering will
reasonably and in good faith agree to include in such offering in excess of any
amount to be registered for Company (or such stockholder with demand
registration rights); and provided, further, that if any Registrable Securities
are not included for this reason, any such reduction in the number of
Registrable Securities will be, after all securities which are the subject of a
Registration Rights Agreement dated as of November 16, 1998 between the Company
and several stockholders including Galen Partners III, L.P., will be included in
future Proposed Registration subject to the allocation provision of this
paragraph.

                                       3
<PAGE>

4. Registration Procedures

         4.1 Actions to be taken by Company. In connection with the registration
of Registrable Securities pursuant to Section 3 hereof, Company will use its
best efforts to effect such registration to permit the sale of such Registrable
Securities in accordance with the proposed method or methods of distribution by
the selling holders thereof and accordingly will:

                  4.1.1 prepare and file with the SEC, as soon as practicable, a
Registration Statement or Registration Statements on any appropriate form under
the Securities Act, which form will be available for the sale of the Registrable
Securities to be covered thereby in accordance with the intended method or
methods of distribution by the selling holders thereof and will include all
financial statements required by the SEC to be filed therewith; Provided that
before filing a Registration Statement or any amendments or supplements thereto
or Prospectus, including in each case documents incorporated by reference,
Company will furnish to the holders of the Registrable Securities covered by
such Registration Statement and the underwriters, if any, copies of all such
documents at least three Trading Days prior to the day they are proposed to be
filed.

                  4.1.2 prepare and file with the SEC such amendments and
post-effective amendments to the Registration Statement as may be necessary to
keep the Registration Statement effective for a period ending on the earlier of
(a) 180 days after the effective date of the Registration Statement or (b)
consummation of the distribution of the securities covered by such Registration
Statement; cause the Prospectus used in connection therewith to be supplemented
by any required Prospectus supplement, and as so supplemented to be filed
pursuant to Rule 424 under the Securities Act; and comply with the provisions of
the Securities Act with respect to the disposition of all securities covered by
such Registration Statement during the period referred to above in accordance
with the intended method or methods of distribution by the selling Holders
thereof set forth in such Registration Statement as amended or supplement to the
Prospectus used in connection therewith;

                  4.1.3 notify the selling Holders of Registrable Securities and
the managing underwriters, if any, promptly, and (if requested by any such
Person) confirm such advice in writing, (a) when the Prospectus or any
Prospectus supplement or post-effective amendment has been filed, and, with
respect to the Registration Statement or any post-effective amendment, when the
same has become effective, (b) of any request by the SEC for amendments or
supplements to the Registration Statement or the Prospectus or for additional
information, (c) of the issuance by the SEC of any stop order suspending the
effectiveness of the Registration Statement or the initiation of any proceedings
for that purpose, (d) of the receipt by Company of any notification with respect
to the suspension of the qualification of the Registrable Securities for sale in
any jurisdiction or the initiation or threatening of any proceedings for such
purpose, and (e) of the happening of any event which makes any statement made in
the Registration Statement, the Prospectus, any amendment or supplement thereto,
or any document incorporated therein by reference untrue or which requires the
making of any changes in the Registration Statement, the Prospectus or any
document incorporated therein by reference in order to make the statements
therein not misleading;

                                       4
<PAGE>

                  4.1.4 upon the occurrence of any event contemplated by Section
4.1.3(e), prepare a supplement or post-effective amendment to the Registration
Statement or the related Prospectus or any document incorporated therein by
reference or file any other required document so that, as thereafter delivered
to the purchasers of the Registrable Securities, the Prospectus will not contain
any untrue statement of a material fact or omit to state any material fact
necessary to make the statements therein not misleading;

                  4.1.5 use its best efforts to obtain the withdrawal at the
earliest possible time of any order suspending or preventing the use of any
Prospectus or suspending the effectiveness of the Registration Statement or any
amendment or supplement thereto or suspending the qualification of any Shares
included in such Registration Statement for sale in any jurisdiction;

                  4.1.6 furnish Quest Diagnostics and each managing underwriter,
if any, without charge, at least one signed copy of the Registration Statement
and every post-effective amendment thereto, including financial statements and
schedules, all documents incorporated therein by reference, and all exhibits
(including those incorporated by reference) and furnish each selling Holder a
conformed copy of each such document;

                  4.1.7 deliver to each selling Holder of Registrable Securities
and the underwriters, if any, without charge, as many copies of the Prospectus
(including each preliminary Prospectus) and any amendment or supplement thereto
as such Persons may reasonably request; consent to the use of the Prospectus or
any amendment or supplement thereto by each of the selling Holders of
Registrable Securities and the underwriters, if any, in connection with the
offering and sale of the Registrable Securities covered by the Prospectus or any
amendment or supplement thereto;

                4.1.8 prior to any public offering of Registrable Securities,
register or qualify or cooperate with the selling Holders of Registrable
Securities, the underwriters, if any, and their respective counsel on a best
efforts basis to register or qualify such Registrable Securities for offer and
sale under the securities or blue sky laws of such jurisdictions as any selling
Holder or underwriter reasonably requests in writing and do any and all other
acts or things necessary or advisable to enable the disposition in such
jurisdictions of the Registrable Securities covered by the Registration
Statement; provided that Company will not be required to (a) qualify generally
to do business in any jurisdiction where it is not then so qualified or (b)
consent to general service of process for all purposes in any jurisdiction where
it is not then subject to process or (c) subject itself to taxation in any such
jurisdiction;

                  4.1.9 cooperate with the selling Holders of Registrable
Securities and the managing underwriters, if any, to facilitate the timely
preparation and delivery of certificates representing Registrable Securities to
be sold and not bearing any restrictive legends; enable such Registrable
Securities to be in such denominations and registered in such names as the
selling Holders or managing underwriters may request at least two Trading Days
prior to any sale of Registrable Securities to the underwriters;

                                       5
<PAGE>

                  4.1.10 provide a CUSIP number for all Registrable Securities,
not later than the effective date of the applicable registration;

                  4.1.11 enter into such agreements and take all such other
actions as may be reasonably required in order to expedite or facilitate the
disposition of such Registrable Securities and in such connection, (a) make such
representations and warranties to the selling Holders of such Registrable
Securities in form, substance and scope as are customarily made by issuers
comparable to Company to underwriters in primary underwritten offerings; (b)
obtain opinions of counsel to Company and updates thereof (which counsel and
opinions (in form, scope and substance) will be reasonably satisfactory to the
managing underwriters, if any, and Quest Diagnostics ) addressed to each selling
holder and the underwriters, if any, covering the matters customarily covered in
opinions requested in underwritten offerings and such other matters as may be
reasonably requested by such holders and underwriters; (c) if the Registrable
Securities are to be distributed pursuant to an Underwritten Offering, obtain
"cold comfort" letters and updates thereof from Company's independent certified
public accountants addressed to the selling Holders of Registrable Securities
and the underwriters, such letters to be in customary form and covering such
matters of the type customarily covered in "cold comfort" letters and as Quest
Diagnostics and underwriters, if any, may reasonably require; and (d) deliver
such documents and certificates as may be requested by Quest Diagnostics, the
selling Holders and the managing underwriters, if any, to evidence compliance
with clause (a) above and with any customary conditions contained in the
underwriting agreement or other agreement entered into by Company. The above
shall be done at each closing under such underwriting or similar agreement or as
and to the extent required thereunder;

                  4.1.12 make available for reasonable inspection by Quest
Diagnostics, each selling Holder, any underwriter, or any attorney or accountant
retained by Quest Diagnostics, any selling Holder or any underwriter, all
financial and other records, pertinent corporate documents and properties of
Company, and cause Company's officers, directors and employees to supply all
information reasonably requested by any such representative, underwriter,
attorney or accountant in connection with such registration; provided, that any
records, information or documents that are designated by Company in writing as
confidential will be kept confidential by such Persons unless disclosure of such
records, information or documents is required by court or administrative order
to become publicly available or becomes publicly available without the fault of
such Person;

                  4.1.13 otherwise use its best efforts to comply with all
applicable rules and regulations of the SEC, and make generally available to its
security holders earnings statements satisfying the provisions of Section 11(a)
of the Securities Act and Rule 158 thereunder, as soon as practicable but in any
event no later than 45 days after the end of any 12-month period (or 90 days' if
such period is a fiscal year) (a) commencing at the end of any fiscal quarter in
which Registrable Securities are sold to underwriters in an Underwritten
Offering, or (b) if not sold to underwriters in such an offering, beginning with
the first month of Company's first fiscal quarter commencing after the effective
date of the Registration Statement, which statements will cover said 12-month
periods;

                                       6
<PAGE>

                  4.1.14 in the case of an S-3 Registration, permit any selling
Holder of Registrable Securities which Holder believes he, she or it may be
deemed to be an underwriter to require the insertion in the Registration
Statement, Prospectus, preliminary prospectus, or any supplement or amendment
thereto, any material which in such Holder's reasonable judgment should be
inserted therein, provided that such material be furnished under circumstances
as will cause it to be subject to the indemnification provisions of Section 6.2
hereto and provided that Company will not be required to insert any material
that it believes to contain any untrue statement of a material fact or any
omission of a material fact required to be stated therein or necessary to make
the statements therein not misleading.

         4.2 Information from Holders. Company may require such Holder of
Registrable Securities as to which any registration is being effected to furnish
to Company such information regarding the distribution of such securities as
Company may from time to time reasonably request in writing.

         4.3 Certain Events. Each Holder of Registrable Securities agrees by
reason of its acquisition and holding of such Registrable Securities that, upon
receipt of any notice from Company of the happening of any event of the kind
described in Section 4.1.3 (c)(e) hereof, such Holder will forthwith discontinue
disposition of Registrable Securities until such Holder's receipt of the copies
of the supplemented or amended Prospectus contemplated by Section 4.1.4 hereof,
or until it is advised in writing by Company that the use of the Prospectus may
be resumed, and, if so directed by Company in writing, such Holder will deliver
to Company (at Company's expense) all copies, other than permanent file copies
then in such Holder's possession, of the Prospectus covering such Registrable
Securities current at the time of receipt of such notice.

5. Registration Expenses

         All expenses incident to Company's performance of or compliance with
this Agreement including without limitation all registration and filing fees,
fees with respect to listings or filings required to be made with NASDAQ or any
national securities exchange on which the Registrable Securities are listed,
fees and expenses of compliance with securities or blue sky laws, printing
expenses of any registration under Section 3, messenger, telephone and delivery
expenses, fees and disbursements of counsel for Company and of all independent
certified public accountants of Company (including the expenses of any special
audit and "cold comfort" letters required by or incidental to such performance),
and securities acts liability insurance if Company so desires, and reasonable
fees and expenses of other Persons retained by Company in connection with the
registration, will be borne by Company; provided however, that the Holders of
the Registrable Securities will be responsible (regardless of whether the
Registration Statement becomes effective) for any (a) underwriting discounts,
commissions, or fees attributable to the sale of the Registrable Securities, (b)
fees and expenses of any counsel, accountants, or other persons retained or
employed by the Holders and (c) transfer taxes, if any.

                                       7
<PAGE>

6. Indemnification

         6.1 Indemnification by Company. Company agrees to indemnify and hold
harmless, to the full extent permitted by law, each Holder of Registrable
Securities, its directors and officers and each Person who controls (within the
meaning of the Securities Act) such Holder against all losses, claims, damages,
liabilities, costs, expenses, fines and penalties (or actions in respect
thereof) (including reasonable attorney's fees and disbursements) caused by (a)
any violation of law by Company in connection with or any breach by Company of
its undertakings hereunder or (b) any untrue or alleged untrue statement of a
material fact contained in any Registration Statement or any amendment or
supplement thereto, Prospectus, preliminary prospectus or amendment or
supplement thereto, or any omission or alleged omission of a material fact
required to be stated therein or necessary to make the statements therein not
misleading, except insofar as the same are caused by or contained in any
information furnished in writing to Company by such Holder expressly for use
therein or by such Holder's failure to deliver a copy of the Registration
Statement or Prospectus or any amendment or supplement thereto after Company has
furnished such Holder with a sufficient number of copies of the same. Company
will also indemnify underwriters, selling brokers, dealer-managers and similar
securities industry professionals participating in the distribution, their
officers and directors and each Person who controls such persons (within the
meaning of the Securities Act) to substantially the same extent as provided
above with respect to the indemnification of the Holders of Registrable
Securities, if requested.

         6.2 Indemnification by Holders of Registrable Securities. In connection
with the Registration, each Holder of Registrable Securities will furnish to
Company in writing such information and affidavits as Company reasonably
requests in connection with any Registration Statement or Prospectus and agrees
to indemnify and hold harmless, to the full extent permitted by law, Company,
its directors and officers and each Person who controls Company (within the
meaning of the Securities Act) against any losses, claims, damages, liabilities
and expenses (including reasonable attorney's fees and disbursements) resulting
from any untrue statement of a material fact contained in the Registration
Statement, Prospectus, preliminary prospectus, amendment or supplement thereto,
or any omission of a material fact required to be stated in the Registration
Statement or Prospectus or preliminary prospectus necessary to make the
statements therein not misleading, to the extent, but only the extent, that such
untrue statement or omission is contained in any information or affidavit so
furnished in writing by such Holder to Company specifically for inclusion in
such Registration Statement, Prospectus, preliminary prospectus, amendment or
supplement thereto, provided that no selling Holder will be required under this
Section 6.2 to pay an amount greater than the dollar amount of the proceeds
received by such selling Holder (net of underwriting commissions and discounts)
with respect to the sale of the Shares giving rise to the claim and the
liability of selling Holders will be several and not joint. Company will be
entitled to receive indemnities from underwriters, selling brokers,
dealer-managers and similar securities industry professionals participating in
the distribution, to the same extent as provided above or otherwise as agreed to
by Company and such Person with respect to information so furnished in writing
by such Person specifically for the inclusion in any Prospectus or Registration
Statement.

                                       8
<PAGE>

         6.3 Conduct of Indemnification Proceedings. Any Person entitled to
indemnification hereunder will (a) give prompt notice to the indemnifying party
of any claim with respect to which it seeks indemnification and (b) permit such
indemnifying party to assume the defense of such claims with counsel reasonably
satisfactory to the indemnified party, provided, however, that any Person
entitled to indemnification hereunder will have the right to employ separate
counsel and to participate in the defense of such claims, but the fees and
expense of such counsel will be at the expense of such Person unless (a) the
indemnifying party has agreed to pay such fees or expenses, or (b) the
indemnifying party has failed to assume the defense of such claim and employ
counsel reasonably satisfactory to such Person, or (c) in the reasonable
judgment of any such Person, based upon advice of its counsel, a conflict of
interest may exist between such Person and the indemnifying party, in any of
which events such reasonable fees and expenses will be borne by the indemnifying
party and the indemnifying party will not have the right to direct the defense
of such action on behalf of the indemnified party, it being understood, however,
that the indemnifying party will not, in connection with any such action or
proceeding or separate but substantially similar or related actions or
proceedings arising out of the same general allegations or circumstances, be
liable for the reasonable fees and expenses of more than one separate firm of
attorneys for all Holders. Anything in this Section to the contrary
notwithstanding, Company will not be liable for any settlement of any such claim
or action effected without its written consent.

         6.4 Contribution. If the indemnification provided for in Sections 6.1
and 6.2 from the indemnifying party is unavailable to or unenforceable by the
indemnified party in respect to any losses, claims, damages, liabilities, costs,
expenses, fines or penalties referred to herein, then the indemnifying party, in
lieu of indemnifying such indemnified party, shall contribute to the amount paid
or payable by such indemnified party as a result of such losses, claims, damages
liabilities, costs, expenses, fines or penalties in such proportion as is
appropriate to reflect the relative fault of the indemnifying party and
indemnified parties in connection with the actions which resulted in such
losses, claims, damages, liabilities, costs, expenses, fumes or penalties, as
well as any other relevant equitable considerations. The relative fault of such
indemnifying party and indemnified parties shall be determined by reference to,
among other things, whether any action in question including any untrue or
alleged untrue statement of material fact or omission or alleged omission to
state a material fact, has been made by, or relates to information supplied by,
such indemnifying party or indemnified parties, and the parties' relative
intent, knowledge, access to information and opportunity to correct or prevent
such action. The amount paid or payable by a party, as a result of the losses,
claims, damages, liabilities, costs, expenses, fines and penalties referred to
above shall be deemed to include, subject to the limitations set forth in
Section 6, any legal or other fees or expenses reasonably incurred by such party
in connection with any investigation or proceeding. Company and the Holders
agree that it would not be just and equitable if contribution pursuant to this
Section 6.4 were determined by pro rata allocation or by any other method of
allocation which-does not take into account the equitable considerations
referred to above. No person guilty of fraudulent misrepresentation (within the
meaning of Section 1 l(f) of the Securities Act) will be entitled to
contribution from any Person who was not guilty of such fraudulent
misrepresentation.

                                       9
<PAGE>

7. Participation in Underwritten Registrations.

         7.1 Required Cooperation. No Holder may participate in any underwritten
registration hereunder unless such Holder (a) agrees to sell such Holder's
securities on the basis provided in any underwriting arrangements approved by
Company and (b) completes and executes all questionnaires, powers of attorney,
indemnities, underwriting agreements and other documents required under the
terms of such underwriting arrangements, provided that no selling Holder of
Registrable Securities in any Underwritten Registration will be required to make
any representation or warranty to Company or the underwriters other than
representations and warranties regarding such Holder and such Holder's intended
method of distribution. Nothing in this Section 7 will be construed to create
any additional rights regarding the registration of Registrable Securities in
any Person otherwise than as set forth therein.

8. Lock-Up

         8.1 In the event of any Proposed Registration involving a proposed
Underwritten Offering of Shares or any security convertible into of exchangeable
for Shares, then Quest Diagnostics and each Holder whose Registrable Securities
are included in a Registration Settlement filed pursuant to Section 3 hereof
will not effect any sale or distribution of any Shares, including any sale
pursuant to Rule 144, without the consent of the managing underwriter for such
Underwritten Offering, during a period (the "Lock-Up Period") commencing 30 days
before (or, if later, the date on which Quest Diagnostics receives notice of
such proposed Underwritten Offering) and ending 90 days (or such fewer number as
the managing underwriter may designate) after the effective date of such
registration statement (or if such Underwritten Offering is pursuant to a shelf
registration, for a period (not to exceed 90 days) commencing upon notice of
such transaction and ending 90 days after pricing of such transaction.
Notwithstanding the foregoing, this Section 8 will not apply to any Underwritten
Offering unless each director and executive officer of Company and (to the
extent that such person has acquired such Securities directly from Company) any
person that Beneficially Owns more than 5% of the outstanding Voting Securities,
agrees in writing to restrictions substantially the same as are set forth in
this Section 8.

9. Miscellaneous

         9.1 Notices. Any notices, requests and other communications hereunder
will be in writing and will be deemed given on the date of delivery, if
delivered personally, by facsimile transmission, or by overnight courier, or
three (3) days after mailing, if sent by registered or certified United States
mail, postage prepaid and return receipt requested, in each case addressed as
follows:

                                       10
<PAGE>

         Name                             Address
         ----                             -------

         To Company                       Q-Med, Inc.
                                          24 Christopher Way
                                          Eatontown, New Jersey  07724
                                          Facsimile: (732) 544-5404

         With a Copy To:                  St. John & Wayne, L.L.C.
                                          Two Penn Plaza East, 10th Floor
                                          Newark, New Jersey  07105
                                          Attention: William P. Oberdorf, Esq.
                                          Facsimile:  (973) 491-3407

         To Quest Diagnostics             Quest Diagnostics Ventures LLC
                                          One Malcolm Avenue
                                          Teterboro, New Jersey 07608
                                          Attention: Treasurer
                                          Facsimile: (201) 729-8905

         With a Copy To:                  One Malcolm Avenue
                                          Teterboro, New Jersey 07608
                                          Attention: General Counsel
                                          Facsimile: (201) 559-2258

except that any of the foregoing may from time to time by written notice to the
others designate another address, which will thereupon become its effective
address for the purposes of this section. Any notice delivered by facsimile will
be confirmed by a written notice delivered in the mails, by overnight courier or
personally; provided that the foregoing will not effect the time for when such
facsimile notice will have been considered to have been delivered, such delivery
being determined as provided in the first sentence of this Section 9.1.

         9.2 Modification and Waiver. No terms and provisions of this Agreement,
including without limitation the terms and provisions contained in this
sentence, will be waived, modified or altered so as to impose any additional
obligations or liability or grant any additional right or remedy and no custom,
payment, act, knowledge, extension of time, favor or indulgence, gratuitous or
otherwise, or words or silence at any time, will impose any additional
obligation or liability or grant any additional right or remedy or be deemed a
waiver or release of any obligation, liability, right or remedy except as set
forth in a written instrument properly executed and delivered by the party
sought to be charged, expressly stating that it is, and the extent to which it
is, intended to be so effective. No assent, express or implied, by any party, or
waiver by any party, to or of any breach of any term or provision of this
Agreement will be deemed to be an assent or waiver to or of such or any
succeeding breach of the same or any other such term or provision.

                                       11
<PAGE>

         9.3 Partial Invalidity. It is the intention of the parties that the
provisions of this Agreement will be enforceable to the fullest extent
permissible under applicable law, and that the unenforceability of any provision
or provisions of this Agreement by such law will not render unenforceable, or
impair, the remainder of the Agreement. If any part of this Agreement will be
determined to be invalid, illegal or unenforceable by any valid Act of Congress
or act of any legislature or by any regulation duly promulgated by the United
States or a state acting in accordance with the law, or declared null and void
by any court of competent jurisdiction, then such part will be reformed, if
possible, to conform to the law and, in any event, the remaining parts of this
Agreement will be fully effective and operative insofar as reasonably possible.

         9.4 Assignment: Successors. This Agreement is not assignable in whole
or in part by either party without the prior written consent of the other party.
Notwithstanding the foregoing, Company may assign this Agreement to a successor,
Affiliate or parent company without the consent of Quest Diagnostics provided
that any such assignment will not release Company from its obligations
hereunder. This Agreement will be binding upon and will inure to the benefit of
the parties hereto and their respective successors and permitted assigns.

         9.5 No Third Party Beneficiaries. Nothing contained in this Agreement
is intend to confer any benefit under this Agreement on anyone other than a
party hereto or any Holder.

         9.6 Governing Law and Jurisdiction. This Agreement and the transactions
contemplated hereby will he construed and enforced in accordance with the laws
of Delaware without regard to the conflict of law provisions thereof.
Jurisdiction and venue for litigation of any dispute, controversy or claim
arising out of or in connection with this Agreement will be only in a United
States federal court or a Delaware State court having subject matter
jurisdiction. Each of the parties hereby expressly submits to the personal
jurisdiction of the foregoing courts located in Delaware, and waives any
objection or defense based on personal jurisdiction or venue that might
otherwise be asserted to proceedings in such courts.

         9.7 Jury Waiver. COMPANY AND QUEST DIAGNOSTICS HEREBY WAIVE TRIAL BY
JURY IN ANY JUDICIAL PROCEEDING INVOLVING ANY MATTER IN ANY WAY ARISING OUT OF
OR RELATED TO THIS AGREEMENT.

         9.8 Termination. All of Company's obligations to register Registrable
Securities pursuant to this Agreement and Quest Diagnostics' obligations under
Section 8.1 shall terminate on the earlier of (i) all Registrable Securities
have been included in a Registration Statement; or (ii) the third anniversary of
the date of this Agreement. Until the Shares are eligible for resale by the
Holders without registration pursuant to Rule 144(k), in order to make available
to the Holders the benefits of certain rules and regulations of the SEC which
may at any time permit the sale of the Shares to the public without
registration, Company agrees to: (a) make and keep public information-available,
as those terms are understood and defined in Rule 144 under the Securities Act;
and (b) use its best efforts to file with the SEC in a timely manner all reports
and other documents required of Company under the Securities Act and the
Exchange Act.

                                       12
<PAGE>

         9.9 No Inconsistent Agreements. The rights granted to the Holders of
Registrable Securities hereunder do not conflict with any existing rights
granted to existing holders of Company securities under any other agreements,
except that certain existing holders of Company securities may have registration
rights which may provide priority to such existing holders in the event of
cutbacks of the securities to be included in certain registrations.

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first written above.

                                  Q-MED, INC.



                                  By:   William T. Schmitt, Jr.
                                       ----------------------------------------
                                  Name: William T. Schmitt, Jr.
                                  Title: Chief Financial Officer



                                  QUEST DIAGNOSTICS VENTURES LLC



                                  By:   Leo C. Farrenkopf, Jr.
                                       ----------------------------------------
                                  Name: Leo C. Farrenkopf, Jr.
                                  Title: Vice President and Assistant Secretary

                                       13